Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Scientists find new clues to how RSV causes disease

Scientists find new clues to how RSV causes disease

Researchers study Lassa fever patient's immune response and viral persistence

Researchers study Lassa fever patient's immune response and viral persistence

FDA grants approval for two drugs to treat hepatitis C virus in children

FDA grants approval for two drugs to treat hepatitis C virus in children

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Study reveals promising mechanism for attacking Ebola virus

Study reveals promising mechanism for attacking Ebola virus

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

New drug combination may reduce need for complex regimens to treat hepatitis C

New drug combination may reduce need for complex regimens to treat hepatitis C

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs